News for GNI Group Ltd. (2160.T)

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IP

**media[568922]**

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (”œGyre”) ( GYRE), a self-sustainable, commercial-stage biotechnology company with clinical

MediLink partnering with BioNTech and Asahi Kasei's $1.1B offer to buy Calliditas Therapeutics lead this week's headlines. Click here to read more.

Revenue: Increased to $113.5 million in 2023, up from $102.3 million in 2022.Net Loss: Reported a net loss of $85.5 million in 2023, compared to a net income o

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update...

Dec 27, 2022 / 01:00PM GMTOperator Greetings. Welcome to the Catalyst Biosciences merger call. (Operator Instructions) Please note, this conference is being rec

GNI Group Updates Other Income and Full Year 2023 Consolidated Earnings Forecasts GNI Group Ltd., today announced...

– Transaction Reflects Increasing Strategic Focus on Proprietary Drug-Eluting Biomatrix Platform – SILVER SPRING, Md., Sept. 18, 2023 (GLOBE NEWSWIRE)...

/PRNewswire/ -- DelveInsight's Acute-On-Chronic Liver Failure Market Insights report includes a comprehensive understanding of current treatment practices,...

This presentation contains statements concerning the current plans, expectations, and strategies of GNI... | May 22, 2023

May 1st , 2023 Company Name: ... | May 1, 2023

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...